Proportions and odds ratios of clearance of total CT-DNA and clearance of viable CT at the rectal site in 184 women who were previously RCT diagnosed (FemCure)
| Clearance of total CT-DNA | Clearance of viable CT | |||||
| n/N (%) | OR (95% CI) | aOR (95% CI) | n/N (%) | OR (95% CI) | aOR (95% CI) | |
| Total | 29/184 (15.8) | 66/184 (35.9) | ||||
| Diagnosis group | ||||||
| (A) vCT and rCT | 21/155 (13.5) | 1† | 1† | 54/155 (34.8) | 1 | 1 |
| (C) vCT (rCT negative) | 8/29 (27.6) | 2.43 (0.95 to 6.19) | 2.74 (0.97 to 7.70) | 12/29 (41.4) | 1.32 (0.59 to 2.97) | 1.34 (0.57 to 3.19) |
| Years of age | ||||||
| 18–20 | 6/41 (14.6) | 1 | 1 | 12/41 (29.3) | 1 | 1 |
| 21–23 | 10/63 (15.9) | 1.10 (0.37 to 3.30) | 1.14 (0.36 to 3.57) | 25/63 (39.7) | 1.59 (0.69 to 3.69) | 1.67 (0.70 to 3.96) |
| ≥24 | 13/80 (16.3) | 1.13 (0.40 to 3.24) | 0.96 (0.31 to 2.99) | 29/80 (36.3) | 1.37 (0.61 to 3.10) | 1.31 (0.55 to 3.07) |
| Days since initial CT diagnosis | ||||||
| 1–7 | 7/43 (16.3) | 1 | 1 | 16/43 (37.2) | 1 | 1 |
| 8–11 | 13/72 (18.1) | 1.13 (0.41 to 3.11) | 0.89 (0.30 to 2.65) | 29/72 (40.3) | 1.14 (0.52 to 2.48) | 0.91 (0.40 to 2.06) |
| ≥12 | 9/69 (13.0) | 0.77 (0.26 to 2.25) | 0.58 (0.18 to 1.89) | 21/69 (30.4) | 0.74 (0.33 to 1.65) | 0.57 (0.24 to 1.35) |
| Study site (STI clinic) | ||||||
| Limburg | 3/46 (6.5) | 1 | 1 | 12/46 (26.1) | 1 | 1 |
| Rotterdam-Rijnmond | 6/35 (17.1) | 2.97 (0.69 to 18.82) | 3.66 (0.79 to 16.99) | 12/35 (34.3) | 1.48 (0.57 to 3.86) | 1.55 (0.57 to 4.17) |
| Amsterdam | 20/103 (19.4) | 3.45 (0.97 to 12.28) | 4.43 (1.16 to 16.91) | 42/103 (40.8) | 1.95 (0.91 to 4.20) | 2.25 (1.00 to 5.06) |
| Self-reported history of CT | ||||||
| Yes | 15/59 (25.4) | 2.70 (1.21 to 6.06) | 2.41 (1.04 to 5.60) | 26/59 (44.1) | 1.67 (0.89 to 3.17) | 1.57 (0.81 to 3.04) |
| No‡ | 14/125 (11.2) | 1* | 1* | 40/125 (32.0) | 1 | 1 |
| Education | ||||||
| Low | 8/57 (14.0) | 1 | na | 20/57 (35.1) | 1 | na |
| Middle‡ | 13/62 (21.0) | 1.63 (0.62 to 4.27) | 25/62 (40.3) | 1.25 (0.59 to 2.63) | ||
| High | 8/65 (12.3) | 0.86 (0.30 to 2.46) | 21/65 (32.3) | 0.88 (0.42 to 1.87) | ||
| Background | ||||||
| Western | 28/171 (16.4) | 1 | na | 62/171 (36.3) | 1 | na |
| Non-Western | 1/13 (7.7) | 0.43 (0.05 to 3.41) | 4/13 (30.8) | 0.78 (0.23 to 2.64) | ||
| No. of sex partners last 3 months | ||||||
| 0 or 1 | 10/57 (17.5) | 1 | na | 15/57 (26.3) | 1 | na |
| 2 or 3 | 15/88 (17.0) | 0.97 (0.40 to 2.33) | 38/88 (43.2) | 2.13 (1.03 to 4.39) | ||
| ≥4 | 4/39 (10.3) | 0.54 (0.16 to 1.86) | 13/39 (33.3) | 1.40 (0.58 to 3.41) | ||
Clearance of total CT-DNA: at follow-up, no total CT-DNA detected at the rectal site; clearance of viable CT: at follow-up, no total CT-DNA or only non-viable CT at the rectal site.
This model includes diagnosis group, age, days since initial CT test (diagnosis) and study site (STI clinic); viability polymerase chain reaction is used to test for viable CT; na (variable not entered into the multivariable model to calculate adjusted ORs).
*Overall p value 0.01 to <0.05, **overall p value 0.001 to <0.01, ***overall p value <0.001.
†Overall p value 0.05 to <0.07.
‡The few cases with unknown information are attributed to this category in analyses.
aOR, OR in the multivariable analyses; CI, Confidence Interval; CT, Chlamydia trachomatis; OR, OR in univariable analyses; rCT, rectal Chlamydia trachomatis; vCT, vaginal Chlamydia trachomatis.